Rivastigmine in subcortical vascular dementia An open 22-month study

[1]  Serge Gauthier,et al.  Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial , 2002, The Lancet.

[2]  Marsel Mesulam,et al.  Widely Spread Butyrylcholinesterase Can Hydrolyze Acetylcholine in the Normal and Alzheimer Brain , 2002, Neurobiology of Disease.

[3]  Annalena Venneri,et al.  Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease , 2002, Neuroreport.

[4]  R. Moretti,et al.  Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow‐up , 2001, European journal of neurology.

[5]  H. Saito,et al.  Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats. , 2000, Toxicology.

[6]  M. Farlow,et al.  A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease , 2000, European Neurology.

[7]  E. Giacobini.  Cholinesterase Inhibitors Stabilize Alzheimer Disease , 2000, Neurochemical Research.

[8]  L. Pantoni,et al.  Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial , 2000, Journal of the Neurological Sciences.

[9]  R. Anand,et al.  An efficacy and safety analysis of Exelon® in Alzheimer’s disease patients with concurrent vascular risk factors , 2000, European journal of neurology.

[10]  M. Weinstock,et al.  Selectivity of Cholinesterase Inhibition , 1999 .

[11]  P. Sachdev,et al.  Differentiation of vascular dementia from AD on neuropsychological tests , 1999, Neurology.

[12]  Y. Agid,et al.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trialCommentary: Another piece of the Alzheimer's jigsaw , 1999 .

[13]  P. Sachdev,et al.  Vascular dementia: diagnosis, management and possible prevention , 1999, The Medical journal of Australia.

[14]  A. Nordberg,et al.  Cholinesterase Inhibitors in the Treatment of Alzheimer’s Disease , 1998, Drug safety.

[15]  D. Jenden,et al.  Cholinesterase Inhibition Improves Blood Flow in the Ischemic Cerebral Cortex , 1997, Brain Research Bulletin.

[16]  T. Erkinjuntti,et al.  Vascular Dementia: Challenge of Clinical Diagnosis , 1997, International Psychogeriatrics.

[17]  A. Burns.  Differential Diagnosis: Discussion , 1997, International Psychogeriatrics.

[18]  P. Manos,et al.  The utility of the ten-point clock test as a screen for cognitive impairment in general hospital patients. , 1997, General hospital psychiatry.

[19]  S. McPherson,et al.  Neuropsychological Aspects of Vascular Dementia , 1996, Brain and Cognition.

[20]  M. Minami,et al.  Cholinergic changes in the hippocampus of stroke-prone spontaneously hypertensive rats. , 1996, Stroke.

[21]  H. Saito,et al.  ANIMAL MODELS OF VASCULAR DEMENTIA WITH EMPHASIS ON STROKE‐PRONE SPONTANEOUSLY HYPERTENSIVE RATS , 1995, Clinical and experimental pharmacology & physiology. Supplement.

[22]  M. Mega,et al.  The Neuropsychiatric Inventory , 1994, Neurology.

[23]  K. Blennow,et al.  The neurochemistry of vascular dementia. , 1994, Dementia.

[24]  T. Wetterling,et al.  The ICD-10 criteria for vascular dementia. , 1994, Dementia.

[25]  M. Minami,et al.  Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rats , 1994, Neuroscience Letters.

[26]  J. Cummings,et al.  Frontal-subcortical circuits and human behavior. , 1993, Journal of psychosomatic research.

[27]  I. Skoog,et al.  A population-based study of dementia in 85-year-olds. , 1993, The New England journal of medicine.

[28]  A. Hofman,et al.  The prevalence of vascular dementia in europe: Facts and fragments from 1980–1990 studies , 1991, Annals of neurology.

[29]  H. Chui.  Dementia. A review emphasizing clinicopathologic correlation and brain-behavior relationships. , 1989, Archives of neurology.

[30]  H. Chui,et al.  The Modified Mini-Mental State (3MS) examination. , 1987, The Journal of clinical psychiatry.

[31]  T. Erkinjuntti,et al.  CT in the differential diagnosis between Alzheimer's disease and vascular dementia , 1987, Acta neurologica Scandinavica.

[32]  C. P. Hughes,et al.  A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.

[33]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[34]  M. Lawton,et al.  Assessment of older people: self-maintaining and instrumental activities of daily living. , 1969, The Gerontologist.

[35]  S. Katz,et al.  STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION. , 1963, JAMA.

[36]  Y. Agid,et al.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. , 1999, BMJ.

[37]  J. Greene,et al.  Measuring behavioural disturbance of elderly demented patients in the community and its effects on relatives: a factor analytic study. , 1982, Age and ageing.